Oral hyaluronic acid: what the research shows for skin and joints

Can hyaluronic acid taken as a capsule or powder hydrate your skin and ease joint complaints? Small studies hint at better skin hydration and elasticity after a few weeks. For joint complaints the results are less clear. There is so far no evidence that oral hyaluronic acid rebuilds cartilage or structurally reverses skin aging.

Hyaluronic acid is a natural part of skin, joint fluid and connective tissue, and its jobs there are well described. What remains open is how much of it reaches those tissues in an active form after you swallow it. That question decides how taking it might affect skin and joints.

What is oral hyaluronic acid?

Hyaluronic acid, or HA for short, is a long-chain sugar molecule from the glycosaminoglycan family. It occurs naturally in joint fluid, in the matrix of the dermis and in connective tissue throughout the body. HA can be swallowed, applied to the skin or injected. Applying it to the skin is called topical use. This article is about HA as an oral supplement.

Putting the study data in context

Clinical studies of oral HA generally report small to moderate effects. The evidence base is modest, though: many studies were industry-funded and ran for only a short time. They often measured skin elasticity with a cutometer or pain on a visual analog scale. These measurements say nothing about structural changes in the tissue.

The evidence ratings below use these criteria:

Strong: At least 2 well-designed randomized controlled trials in humans with a clinically meaningful endpoint, ideally backed by a meta-analysis showing the same direction of effect. Alternatively, a single very large randomized controlled trial with more than 1,000 participants and reproducible methods.
Moderate: At least 1 randomized controlled trial in humans with a clinically meaningful endpoint; or several smaller randomized controlled trials with mixed results; or a single high-quality randomized controlled trial on a surrogate endpoint.
Limited: Only small studies with fewer than 50 participants, short studies of less than 8 weeks or methodologically weak studies in humans; or only observational data in humans.
Animal studies / preclinical only: No completed human studies of the effect in question. Only in vitro data, animal models or safety data from phase 1 trials are available.
Anecdotal: No controlled evidence of any kind. The basis is case reports, personal accounts, mechanistic plausibility or marketing claims without support from published data.

Skin hydration and the appearance of wrinkles: moderate evidence

A randomized controlled trial in 150 people on oral sodium hyaluronate reported improvements in skin hydration, barrier function and visible signs of aging over 12 weeks. The size of the study and its funding limit how much it can tell us.

A 12-week, double-blind, placebo-controlled study with a small sample also found less pronounced wrinkles and improved dry skin. This fits with the results of a randomized double-blind study on oral HA and various skin characteristics.

Taken together, these findings suggest that oral HA might improve skin hydration and surface-related elasticity over 8–12 weeks. Most of the studies are small and industry-funded. They rely on cutometer measurements or self-reports. Tissue studies showing remodeling of the skin are missing, so a structural reversal of aging cannot be inferred from these results.

Joint complaints in mild to moderate knee osteoarthritis: limited evidence in adults

Early studies include a randomized pilot study on HA from rooster combs in knee osteoarthritis, which assessed pain and quality of life, and a study in people with obesity and knee osteoarthritis looking at pain, function and inflammatory cytokines. The results apply to the adults studied, who had mild to moderate symptoms.

More recent work has also looked at combination products. In an 8-week randomized controlled trial in mild knee osteoarthritis, symptoms improved moderately with low-molecular-weight HA combined with glucosamine and chondroitin. With a combination like this, the share contributed by HA cannot be determined.

Interpreting small changes is made harder by the large placebo effect in osteoarthritis trials. A systematic review describes large and consistent responses to intra-articular placebo treatments in knee osteoarthritis. Those results concern injections and cannot be carried straight over to oral products. They do show why an observed improvement, on its own, is not a reliable statement about what a product does.

Whether and how current osteoarthritis guidelines classify oral HA cannot yet be answered reliably from the overview of guideline recommendations cited here. A recommendation as standard treatment cannot be derived from it at present.

Boosting the body’s own HA production in target tissue: animal studies / preclinical evidence only

Cell experiments suggest that HA fragments combined with probiotics might stimulate the body’s own HA production in skin cells. This gave rise to the hypothesis of a gut-skin axis: processes in the gut might trigger effects in the skin. In rodents, low-molecular-weight HA was detected in plasma and peripheral tissues after oral dosing. Because of differences between species, these results transfer to humans only to a limited degree.

In experimental models, HA tetrasaccharides were also able to penetrate skin tissue. This finding makes an effect of small HA fragments biologically plausible. It does not show, however, that usual oral supplement doses increase the body’s own HA production in the human dermis or joint lining. The studies described here contain no direct evidence of that.

“Reverses skin aging” / cartilage regeneration: anecdotal evidence

The controlled human studies described here show neither that oral HA changes the course of disease nor that it reverses structural aging processes. Over a few weeks, they recorded skin measurements or pain on visual analog scales. None of the cited studies examined cartilage volume, collagen architecture or remodeling of the dermal matrix as a primary endpoint.

Better surface skin hydration over 12 weeks therefore does not justify a marketing claim like “reverses aging.” Rebuilding cartilage in existing osteoarthritis has not been shown either. Nor is there evidence that oral HA can replace intra-articular HA injections in symptomatic knee osteoarthritis.

No FDA-approved indication of oral HA is listed for any condition; the US information refers to May 2026. Taking it instead of having joint or skin conditions checked by a doctor is not supported by the evidence.

Structure and origin of oral HA

HA is made of repeating pairs of two sugar building blocks, glucuronic acid and N-acetylglucosamine. These pairs are called disaccharide units. They form chains of very different lengths, from small oligosaccharides to polymers of more than one million daltons.

Molecular weight changes with chain length. It affects both absorption and the biological effects that follow. The biological functions and medical uses of HA range from binding water in tissues and lubricating joints to delivering drugs.

Chemistry: structure and charge

Each repeating unit of the HA chain links D-glucuronic acid to N-acetyl-D-glucosamine. Short oligosaccharides weigh a few kilodaltons (kDa). High-molecular-weight polymers reach more than one million daltons (Da).

At physiological pH, HA carries a strong negative charge, which chemists call anionic. As a result it binds a lot of water and crosses cell membranes poorly by passive means. One explanatory model for oral absorption therefore starts with breakdown in the gut: enzymes split the intact polymer into fragments that might then enter the circulation.

Molecular weight also affects how HA interacts with receptors such as CD44 and TLR4. In connective tissue, joint fluid and the extracellular matrix of the dermis, HA serves as a structural scaffold and water reservoir. For more detail, see the reviews on the biology and uses of HA and on uses in ophthalmology, rheumatology and dermatology.

Origin and history of oral supplements

HA for supplements comes mainly from three sources. Microbial fermentation with Streptococcus zooepidemicus is described as the dominant method today. Historically, HA was extracted from rooster combs; this method is now used less often. Marine organisms are another possible raw material. HA has been isolated from several aquatic species and some product labels state a marine origin.

HA was first isolated in 1934 from the vitreous humor of cattle eyes. Medical uses followed, first in ophthalmology and later in orthopedics and dermatology.

Oral supplementation grew mainly out of Japanese clinical research in the early 2000s. Early studies on taking HA for dry skin paved the way for the consumer market, but were often industry-funded. One publication covers ingested hyaluronan for moisturizing dry skin. Overall, research on oral use is younger and less consistent in its methods than research on injections.

How oral hyaluronic acid might work

What actually arrives in the skin or joints after digestion? That question goes a long way toward deciding whether swallowed HA can act there. The known jobs of the body’s own HA do not answer it. The leading hypothesis holds that fragments formed in the gut are the active components. Distribution of the intact polymer is considered less plausible.

Mechanism: fragments, receptors and the gut-tissue axis

In this model, gut microbes and the body’s own enzymes first break the ingested HA down into oligosaccharide fragments. Only after that might a meaningful amount be absorbed into the circulation.

The fragments might cross the gut lining and trigger signals in dermal fibroblasts and synovial cells via CD44 and receptors of the TLR family. These are cells of the dermis and of the joint lining. Such signals might in turn stimulate the body’s own HA synthesis in these tissues.

Another explanation involves the gut-skin and gut-joint axes. HA fragments might change the gut microbiome and immune activity and in this way influence skin and joints. Joint lubrication depends, among other things, on the concentration and molecular weight of the body’s own HA. That would be one possible point where supplementation could come in.

The work cited for this covers molecular weight, gut microbiota and bioavailability as well as proposed cellular effects linked to the gut-skin axis. The fact that small HA tetrasaccharides can penetrate skin tissue by passive diffusion in experimental studies makes biological activity of such fragments plausible.

Cell and animal models therefore support parts of the proposed mechanism. Whether it also plays out in human tissue at usual supplement doses has not been directly shown.

Pharmacokinetics: what actually gets absorbed

Intact high-molecular-weight HA has low oral bioavailability. Its size, its negative charge and its strong water binding make passive absorption in the gut difficult.

In rodents, low-molecular-weight HA was detectable in plasma and peripheral tissues after oral dosing. Because of differences between species, this finding cannot be transferred directly to humans. Data on how oral HA is absorbed and distributed in the human body remain sparse.

A model in which oligosaccharides formed in the gut enter the circulation seems more plausible. That HA tetrasaccharides can penetrate the skin by passive diffusion describes one possible route by which small fragments could reach tissue. It does not follow, however, that effective amounts reach human skin after oral intake. Bioavailability in humans remains a major open question.

Forms, molecular weight and quality markers

When comparing oral HA products, the stated molecular weight helps. It affects how the polymer behaves in the gut, how its fragments are absorbed and what receptor signals they might trigger. Products with different forms are therefore not automatically equivalent.

For low-molecular-weight HA, usually 5–50 kDa, the absorption data are better characterized. Shorter chains need less breakdown in the gut before they reach a size at which they might be able to pass the gut lining. The fragment-absorption model applies most directly to this form.

High-molecular-weight HA of more than 1 million Da is the traditional form in supplements. It has to be fragmented more extensively before any systemic absorption. Which fragments result is less predictable. Oral products most often contain sodium hyaluronate, the salt form of HA. At physiological pH it corresponds to free hyaluronic acid in terms of the hyaluronate form present.

Origin can also influence the choice. HA is obtained from rooster combs, marine organisms or microbial fermentation. Fermentation with Streptococcus zooepidemicus is described as the dominant method today. It can avoid allergen problems linked to animal raw materials. That does not automatically make the finished product allergen-free, though.

Independent product testing or certification, for example by USP, NSF International or ConsumerLab, is among the quality markers you can check. The Certificate of Analysis (COA) should state the molecular weight. Since molecular weight and formulation affect the cosmetic and biological behavior of HA, this figure is a basic quality marker. Many products leave it out. For allergy risks, a confirmed origin from microbial fermentation also matters.

Regulatory status

The regulatory information refers to the United States and to May 2026. It says nothing about the German or European legal framework.

In the US, oral hyaluronic acid products are regulated as dietary supplements under the Dietary Supplement Health and Education Act (DSHEA). They do not need FDA approval before going on the market. As of the stated date, no oral HA product has an FDA-approved clinical indication.

Injectable products follow different rules. Intra-articular HA injections are classified here as Class III medical devices, with some products approved through the PMA process for specific pain indications in knee osteoarthritis. The exact approval pathway still needs to be clarified product by product. HA dermal fillers are FDA-approved medical devices for aesthetic uses.

The approved HA-based products cover uses in ophthalmology, orthopedics and aesthetics. Their approvals do not extend to oral supplements. The evidence base, dosing logic and regulatory oversight differ considerably depending on the route of use.

Safety profile

The available safety data on oral HA come from small randomized controlled trials lasting 8–24 weeks. No serious adverse events were documented in them. That is reassuring, but it does not allow a comprehensive statement about long-term safety: large long-term datasets are missing.

Reported side effects

The main studies of oral HA mostly describe mild adverse events. For the 12-week double-blind skin study, no serious events are reported; mild gastrointestinal complaints were the most common. The sodium hyaluronate study in 150 people also described good tolerability over 12 weeks. In the Hyal-Joint pilot study in knee osteoarthritis, mild gastrointestinal symptoms and occasional headaches were reported at the doses tested.

Allergic reactions are possible with products made from rooster combs. For people with a poultry or egg allergy, the origin of the product therefore matters before taking it.

In the study literature summarized here, no serious adverse event was attributed to oral HA at supplement doses. The documented side effects were mild and rare. This observation is limited to small groups and short study periods.

Drug interactions

There are few data on drug interactions. The concerns below rest mostly on theoretical considerations and do not allow a reliable assessment of individual risk.

With anticoagulants, an interaction is considered theoretically possible: HA acts on cell-surface receptors that might influence inflammatory cascades. A clinical interaction at usual oral supplement doses is not documented in the information cited.
With immunosuppressants in the setting of active cancer, the theoretical concern involves the CD44 receptor. This proposed pathway for HA fragments is also relevant in oncology. Whether taking additional HA is appropriate is a decision for the treating physician.
No serious interactions at supplement doses are described. Because the evidence is thin, however, such interactions have not yet been characterized in any detail in published clinical data.

If you take several medicines, raise an added HA supplement with your doctor before starting it. The theoretical considerations also do not support reliably classing the interactions as “minor.”

Pregnancy, breastfeeding and organ function

For isolated HA supplements, there are not enough controlled safety data in people who are pregnant or breastfeeding. The body’s own HA does play important roles in fetal development and tissue remodeling. That does not tell us whether additional oral doses are safe. They have not been adequately studied in pregnancy and breastfeeding; the absence of such data does not, on its own, demonstrate harm.

In people with impaired liver or kidney function, the existing literature documents no substance-specific safety problems. Recommendations for dose adjustment are also missing. The data are therefore not sufficient for firm statements about safety in these conditions. With significant liver or kidney disease, the decision whether to take it lies with the treating physician.

Who should avoid oral hyaluronic acid

Known allergies, missing safety data and theoretical concerns can all argue against taking it on your own. They are supported by evidence to very different degrees and should not be read as equivalent contraindications.

For people who are pregnant or breastfeeding, controlled human safety data on supplement doses are lacking.
With a known allergy to HA products made from rooster combs or marine sources, the options are to avoid it or, where appropriate, to use microbially fermented HA. Whether an alternative product is suitable also depends on its other ingredients.
With active cancer, the decision belongs with a doctor because of possible concerns about signaling through the HA receptor CD44.
With existing osteoarthritis and symptoms that need assessment, a rheumatology or orthopedic examination is indicated. Oral HA has no proven benefit as a substitute for necessary assessment or treatment.
For children, supplement doses have not been adequately characterized.

In these situations, involve a treating health professional before taking it, someone who knows your complete medication list and relevant lab results.

Oral vs. topical hyaluronic acid: how the routes differ

Which route makes sense depends on the result you want. The data for swallowing HA and for applying it to the skin are different.

Origin and chemistry: Oral HA is usually microbially fermented sodium hyaluronate. It is swallowed as a polymer or oligosaccharide and processed in the gut. Topical HA is applied directly to the skin surface. Whether this rules out all systemic exposure cannot be stated across the board for every formulation.
Bioavailability: In the model described, oral HA is fragmented in the gut before systemic absorption. Intact polymers are absorbed only to a small extent. Topical HA binds moisture on the horny outer layer, the stratum corneum. High-molecular-weight forms penetrate the dermis only minimally; tetrasaccharides can penetrate further by passive diffusion.
Strongest evidence: The oral studies cited include a study in 150 people in which sodium hyaluronate improved skin hydration and signs of aging over 12 weeks. For topical use there is an extensive aesthetic dermatology literature on surface hydration and short-term improvements in the appearance of wrinkles. None of this amounts to a direct comparison of the two routes.
Dose range studied: Published oral studies tested 80–200 mg per day over 8–12 weeks. Topical use depends on the formulation; beyond the product’s percentage concentration, there is no standard dose.
Key safety differences: With oral intake, mild gastrointestinal complaints and occasional headaches have been documented. With topical use, contact dermatitis is rare. Ruling out systemic exposure across the board for topical products has not been conclusively examined.
Relative cost: A reliable price comparison is not possible with the information available. Specific currency amounts or reliable price ranges are missing.
Regulatory status: In the US, oral products count as dietary supplements under DSHEA with no FDA-approved indication, as of May 2026. Topical products are described as cosmetics or over-the-counter products, which are subject to separate FDA rules.

For everyday hydration of the skin surface, topical HA is the more direct route. It works locally and immediately, without needing absorption through the gut. For joint complaints or possible effects in tissue, oral HA has a limited study base.

Among oral products, low-molecular-weight formulations have been studied more thoroughly for bioavailability. Whether they also beat high-molecular-weight HA on clinical outcomes remains open because the study findings are inconsistent. In topical products, low-molecular-weight HA can penetrate deeper skin layers than high-molecular-weight HA. This difference matters when comparing formulations.

One suggested way to track skin changes is to record perceived hydration and elasticity over 8–12 weeks at consistent measurement times. For joint inflammation, the inflammatory marker hs-CRP is also discussed. It does not, however, provide specific evidence that oral HA works.

Tracking results: biomarkers and rating scales

How can you tell whether anything has changed? What you can track is mainly symptoms and skin characteristics, for example with joint pain scales or skin hydration measurements. No reliable substance-specific serum biomarker for monitoring the success of an oral HA supplement is identified here. Whether additional lab values make sense depends on the clinical question.

hs-CRP reflects a systemic inflammation signal and is discussed mainly for joint complaints as a possible supplementary value. The proposed link to HA intake rests on the assumed anti-inflammatory mechanism of HA fragments. Studies of oral HA in knee osteoarthritis recorded inflammatory cytokines as well as pain. That does not, however, yield a validated HA-specific efficacy test with repeat measurement after 8–12 weeks.
Vitamin D (25-OH) can, because of its established role in the musculoskeletal system, add useful information about joint complaints in a clinical context. As a baseline value it is not HA-specific. Deficiency is common and treatable regardless of HA intake.
For skin hydration and elasticity, cutometer measurements, POSAS and VISIA are cited. These methods are neither the same kind of subjective scale nor all self-report scales. What each one does and how it has been validated for the HA endpoints mentioned still needs to be clarified. The suggested tracking scheme is a baseline on day 0 and a follow-up after 12 weeks under consistent timing conditions.
The visual analog scale for joint pain and WOMAC are validated instruments in osteoarthritis research. Recording them on day 0 and after 8–12 weeks under comparable physical load can make changes within one person visible. Because of the pronounced placebo effect in osteoarthritis trials, though, it is hard to attribute an individual improvement confidently to HA intake.

Subjective reports and, where clinically justified, inflammatory or other lab values can describe changes. A baseline hs-CRP offers at most an objective reference point, not proof that the product works.

Even with baseline values, the product’s effect, the placebo effect, the natural course and regression to the mean cannot be reliably separated in a single person. Regression to the mean here means that unusually severe symptoms may sit closer to their usual level at a later measurement, even without effective treatment. When judging the studies, the frequent industry funding adds to this. Based on the information cited, routine lab tests for monitoring HA intake have been shown to be neither necessary nor suitable as a validated method.

When to see a doctor

Persistent joint pain, suspected osteoarthritis or skin changes that could point to a dermatological condition are reasons to get checked by a doctor. Treating yourself with supplements does not replace that examination.

In knee osteoarthritis, oral HA is classed at most as a supportive option, well behind physical therapy, weight management and medication options supervised by a doctor. The review on managing knee osteoarthritis cited for this is a narrative review. A firm guideline recommendation on oral HA cannot be derived from it.

If symptoms are the reason for taking it, a rheumatology or dermatology assessment may be the right next step. hs-CRP and vitamin D are possible supplementary baseline values for questions about inflammation and the musculoskeletal system. Whether they are needed in a given case depends on the symptoms and the doctor’s question. A blanket test before taking HA is not justified on this basis.

Frequently asked questions

What are oral hyaluronic acid supplements?

These products contain hyaluronic acid (HA) and are marketed for joint complaints and skin hydration. HA is a long-chain sugar molecule from the glycosaminoglycan family. In the body it occurs in joint fluid, in the matrix of the dermis and in connective tissue.

HA can also be applied topically to the skin or injected. The supplements discussed here are intended for oral use only.

Do oral hyaluronic acid supplements actually work on joints or skin?

For skin, there is evidence of moderate improvements in surface hydration and elasticity over 8–12 weeks. Studies using 80–200 mg per day for 8–12 weeks also report better wrinkle ratings. These include a 12-week skin study in dry skin and wrinkles. The study base is small and often industry-funded; overall, some improvement in surface hydration and elasticity seems possible.

In mild to moderate knee osteoarthritis, moderate improvements in pain and function have been described, for example in the Hyal-Joint pilot study. The joint data remain limited and inconsistent. They do not support a recommendation as regular therapy; the exact position of current osteoarthritis guidelines is still to be clarified.

What doses have been studied?

Studies used 80–200 mg of oral hyaluronic acid per day. Skin studies mostly lasted 8–12 weeks, joint studies from 8 weeks to 6 months.

Most of the work with positive bioavailability findings used low-molecular-weight HA. This includes the cited pharmacokinetic studies. The amounts used in studies are not an individual dosing recommendation.

What side effects can oral hyaluronic acid have?

The most commonly reported are mild gastrointestinal complaints and occasional headaches. The evidence for this comes from a pilot study in knee osteoarthritis and a 12-week skin study.

No serious adverse events were reported at the doses tested. This statement is limited to the groups and time periods studied; long-term safety data are still not available in sufficient quantity.

Are oral hyaluronic acid supplements FDA-approved?

No FDA approval for a therapeutic indication is listed for oral HA products. In the US they are sold as dietary supplements under the Dietary Supplement Health and Education Act (DSHEA).

Injectable HA products go through different regulatory procedures. Dermal fillers are FDA-approved medical devices. The exact approval pathway for intra-articular HA in knee osteoarthritis has to be clarified product by product. Approvals for injectable products do not apply to oral supplements.

How do oral, topical and injectable hyaluronic acid differ?

Oral hyaluronic acid is swallowed and processed in the gut. Small randomized controlled trials provide hints of effects on skin and joint endpoints. Bioavailability in humans remains an open question. Low-molecular-weight forms show higher bioavailability in pharmacokinetic studies, but results vary between studies.

Topical hyaluronic acid binds moisture on the skin surface. Systemic absorption or exposure cannot be ruled out across the board for every formulation.

Injectable hyaluronic acid is used, among other things, intra-articularly in knee osteoarthritis and as a dermal filler for aesthetic purposes. How well a use is supported has to be judged separately for each indication and each product. A blanket ranking that credits injectable HA as a whole with the strongest evidence does not do justice to the different uses. And an established use in knee osteoarthritis does not mean that all guidelines recommend it.

Who should avoid oral hyaluronic acid supplements?

Because controlled human safety data are lacking, people who are pregnant or breastfeeding are advised not to use oral HA products. If you take anticoagulants or have active cancer, talk to your treating health professional first. Clinical data on drug interactions at supplement doses are sparse; the concerns rest mainly on theoretical considerations.

Which blood tests make sense before taking HA?

No reliable serum biomarker for monitoring the success of an HA supplement is identified in the information cited. Changes are tracked through, among other things, reports on skin hydration or a visual analog scale for joint pain.

With joint inflammation, high-sensitivity C-reactive protein (hs-CRP) can be informative in the context of the whole clinical picture. Vitamin D can also add information about joint complaints. Whether these or other lab values are needed depends on the symptoms and the doctor’s question.

One suggested tracking scheme is measurements on day 0 and after 12 weeks, each at the same lab and with a consistent morning testing routine. This scheme, however, has not been validated as a way to monitor HA intake. Changes in the values do not prove that the hyaluronic acid had an effect.

References and sources

Vasvani S, Kulkarni P, Rawtani D (2020). Hyaluronic acid: A review on its biology, aspects of drug delivery, route of administrations and a special emphasis on its approved marketed products and recent clinical studies. International journal of biological macromolecules, 151, 1012-1029. https://doi.org/10.1016/j.ijbiomac.2019.11.066
PubMed: https://pubmed.ncbi.nlm.nih.gov/31715233/
Huynh A, Priefer R (2020). Hyaluronic acid applications in ophthalmology, rheumatology, and dermatology. Carbohydrate research, 489, 107950. https://doi.org/10.1016/j.carres.2020.107950
PubMed: https://pubmed.ncbi.nlm.nih.gov/32070808/
Giji S, Arumugam M (2014). Isolation and characterization of hyaluronic acid from marine organisms. Advances in food and nutrition research, 72, 61-77. https://doi.org/10.1016/B978-0-12-800269-8.00004-X
PubMed: https://pubmed.ncbi.nlm.nih.gov/25081077/
Kawada C, Yoshida T, Yoshida H, Matsuoka R, Sakamoto W, Odanaka W, Sato T, Yamasaki T, Kanemitsu T, Masuda Y, Urushibata O (2014). Ingested hyaluronan moisturizes dry skin. Nutrition journal, 13, 70. https://doi.org/10.1186/1475-2891-13-70
PubMed: https://pubmed.ncbi.nlm.nih.gov/25014997/
Šimek M, Turková K, Schwarzer M, Nešporová K, Kubala L, Hermannová M, Foglová T, Šafránková B, Šindelář M, Šrůtková D, Chatzigeorgiou S, Novotná T, Hudcovic T, Velebný V (2023). Molecular weight and gut microbiota determine the bioavailability of orally administered hyaluronic acid. Carbohydrate polymers, 313, 120880. https://doi.org/10.1016/j.carbpol.2023.120880
PubMed: https://pubmed.ncbi.nlm.nih.gov/37182970/
Galla R, Mulè S, Ferrari S, Molinari C, Uberti F (2025). Non-Animal Hyaluronic Acid and Probiotics Enhance Skin Health via the Gut-Skin Axis: An In Vitro Study on Bioavailability and Cellular Impact. International journal of molecular sciences, 26(3). https://doi.org/10.3390/ijms26030897
PubMed link cited in the relevant topic context; attribution to be checked because of the inconsistency described above: https://pubmed.ncbi.nlm.nih.gov/39940667/
Hui AY, McCarty WJ, Masuda K, Firestein GS, Sah RL (2012). A systems biology approach to synovial joint lubrication in health, injury, and disease. Wiley interdisciplinary reviews. Systems biology and medicine, 4(1), 15-37. https://doi.org/10.1002/wsbm.157
PubMed: https://pubmed.ncbi.nlm.nih.gov/21826801/
Takagi Y, Kage M (2025). Hyaluronan Tetrasaccharides Penetrate into the Skin by Passive Diffusion and Contribute to Skin Health. Chemical & pharmaceutical bulletin, 73(4), 284-290. https://doi.org/10.1248/cpb.c23-00909
PubMed: https://pubmed.ncbi.nlm.nih.gov/40175107/
Mannino F, Irrera N, Pallio G, Bitto A (2024). Steady state plasma and tissue distribution of low molecular weight hyaluronic acid after oral administration in mice. Natural product research, 38(5), 773-780. https://doi.org/10.1080/14786419.2023.2197598
PubMed link cited in the pharmacokinetics section; attribution to be checked because of the inconsistency described above: https://pubmed.ncbi.nlm.nih.gov/37081790/
Dolečková I, Kušnierik P, Berka V, Šimek M, Matějková I, Prokopec F, Ovesná P (2025). Oral sodium hyaluronate improves skin hydration, barrier function and signs of aging: a randomized, double-blind, placebo-controlled trial in 150 healthy adults. Scientific reports, 16(1), 2941. https://doi.org/10.1038/s41598-025-32758-5
PubMed: https://pubmed.ncbi.nlm.nih.gov/41422283/
Hsu TF, Su ZR, Hsieh YH, Wang MF, Oe M, Matsuoka R, Masuda Y (2021). Oral Hyaluronan Relieves Wrinkles and Improves Dry Skin: A 12-Week Double-Blinded, Placebo-Controlled Study. Nutrients, 13(7). https://doi.org/10.3390/nu13072220
PubMed: https://pubmed.ncbi.nlm.nih.gov/34203487/
Gao YR, Wang RP, Zhang L, Fan Y, Luan J, Liu Z, Yuan C (2023). Oral administration of hyaluronic acid to improve skin conditions via a randomized double-blind clinical test. Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), 29(11), e13531. https://doi.org/10.1111/srt.13531
PubMed: https://pubmed.ncbi.nlm.nih.gov/38009035/
Kalman DS, Heimer M, Valdeon A, Schwartz H, Sheldon E (2008). Effect of a natural extract of chicken combs with a high content of hyaluronic acid (Hyal-Joint) on pain relief and quality of life in subjects with knee osteoarthritis: a pilot randomized double-blind placebo-controlled trial. Nutrition journal, 7, 3. https://doi.org/10.1186/1475-2891-7-3
PubMed: https://pubmed.ncbi.nlm.nih.gov/18208600/
Nelson FR, Zvirbulis RA, Zonca B, Li KW, Turner SM, Pasierb M, Wilton P, Martinez-Puig D, Wu W (2015). The effects of an oral preparation containing hyaluronic acid (Oralvisc®) on obese knee osteoarthritis patients determined by pain, function, bradykinin, leptin, inflammatory cytokines, and heavy water analyses. Rheumatology international, 35(1), 43-52. https://doi.org/10.1007/s00296-014-3047-6
PubMed: https://pubmed.ncbi.nlm.nih.gov/24899570/
Wang SJ, Wang YH, Huang LC (2021). The effect of oral low molecular weight liquid hyaluronic acid combination with glucosamine and chondroitin on knee osteoarthritis patients with mild knee pain: An 8-week randomized double-blind placebo-controlled trial. Medicine, 100(5), e24252. https://doi.org/10.1097/MD.0000000000024252
PubMed: https://pubmed.ncbi.nlm.nih.gov/33592868/
Vannabouathong C, Bhandari M, Bedi A, Khanna V, Yung P, Shetty V, Khan M (2018). Nonoperative Treatments for Knee Osteoarthritis: An Evaluation of Treatment Characteristics and the Intra-Articular Placebo Effect: A Systematic Review. JBJS reviews, 6(7), e5. https://doi.org/10.2106/JBJS.RVW.17.00167
PubMed: https://pubmed.ncbi.nlm.nih.gov/30020117/
Gray B, Gibbs A, Bowden JL, Eyles JP, Grace S, Bennell K, Geenen R, Sharon Kolasinski, Barton C, Conaghan PG, McAlindon T, Bruyere O, Géczy Q, Hunter DJ (2024). Appraisal of quality and analysis of the similarities and differences between osteoarthritis Clinical Practice Guideline recommendations: A systematic review. Osteoarthritis and cartilage, 32(6), 654-665. https://doi.org/10.1016/j.joca.2024.02.890
PubMed: https://pubmed.ncbi.nlm.nih.gov/38452880/
Juncan AM, Moisă DG, Santini A, Morgovan C, Rus LL, Vonica-Țincu AL, Loghin F (2021). Advantages of Hyaluronic Acid and Its Combination with Other Bioactive Ingredients in Cosmeceuticals. Molecules (Basel, Switzerland), 26(15). https://doi.org/10.3390/molecules26154429
PubMed: https://pubmed.ncbi.nlm.nih.gov/34361586/
Bravo B, Correia P, Gonçalves Junior JE, Sant’Anna B, Kerob D (2022). Benefits of topical hyaluronic acid for skin quality and signs of skin aging: From literature review to clinical evidence. Dermatologic therapy, 35(12), e15903. https://doi.org/10.1111/dth.15903
PubMed: https://pubmed.ncbi.nlm.nih.gov/36200921/
Shtroblia V, Petakh P, Kamyshna I, Halabitska I, Kamyshnyi O (2025). Recent advances in the management of knee osteoarthritis: a narrative review. Frontiers in medicine, 12, 1523027. https://doi.org/10.3389/fmed.2025.1523027
PubMed: https://pubmed.ncbi.nlm.nih.gov/39906596/